CINRYZE is the first and only therapy indicated in the U.S. to help prevent angioedema attacks in pediatric patients with hereditary angioedema (HAE) as young as 6 Shire is the only drug developer to complete a pediatric study for the … Read the full press release
Posted in Healthcare, Ireland, Pharma & Biotech
Tagged Andreas Busch Ph.D., angioedema, biotechnology, CINRYZE, FDA, hereditary angioedema, rare diseases, Shire
New facility will add 30% capacity to Shire’s internal plasma manufacturing network once fully operational Expanded capacity supports continued strong growth of Shire’s leading immunoglobulin portfolio and further strengthens ability to deliver complex therapies for rare immune-mediated conditions DUBLIN, 25-Jun-2018 … Read the full press release
Clinical and real-world insights on recombinant human parathyroid hormone (1-84) (rhPTH[1-84]) and the management of chronic hypoparathyroidism to be presented Hypoparathyroidism is a rare endocrine disease that can have a significant impact on patients New data highlight Shire’s commitment to … Read the full press release
DUBLIN, 16-Jan-2018 — /EuropaWire/ — At Shire, we’ve been committed to the hemophilia community and the lives of every patient afflicted with this disease for more than 70 years. We are very proud of this legacy and take our role as … Read the full press release
Posted in Healthcare, Ireland, Pharma & Biotech
Tagged Chugai, Genentech, Hemlibra, hemophilia, Howard Mayer M.D., IP, patent, rare diseases, Roche, Shire
Marketing Authorization will enable patient access to ADYNOVI throughout Europe ZUG, 16-Jan-2018 — /EuropaWire/ — Shire plc (LSE: SHP, NASDAQ: SHPG), the global biotechnology leader in rare diseases, announced today that the European Commission (EC) has granted Marketing Authorization for ADYNOVI … Read the full press release
Posted in Healthcare, Pharma & Biotech, Switzerland
Tagged ADYNOVI, bleeding, Dr. Peter Foertig MD, hemophilia A, rare diseases, Shire, treatment options
Mydayis, which is now available in the U.S., demonstrated improvements lasting up to 16 hours post-dose, beginning at 2 or 4 hours post-dose, compared to placebo, in total score on a skill-adjusted math test that measures attention in ADHD Lexington, … Read the full press release
Posted in Healthcare, Ireland, Pharma & Biotech
Tagged ADHD, Dr. Matthew Brams, MYDAYIS, Shire
Lifitegrast, if approved, would be the first and only new class treatment to address the signs and symptoms of dry eye disease in adults in Europe ZUG, 16-Aug-2017 — /EuropaWire/ — Shire plc (LSE: SHP, NASDAQ: SHPG) announces that the Marketing Authorization … Read the full press release
Posted in Healthcare, Pharma & Biotech, Switzerland
Tagged dry eye disease, Howard Mayer M.D., lifitegrast, Shire
Latest Research Supports Greater Understanding of the Evolving Needs of Adults with ADHD Lexington, M.A., 18-May-2017 — /EuropaWire/ — Shire plc (LSE: SHP, NASDAQ: SHPG) will present research on the evolving needs of adults living with Attention-Deficit/Hyperactivity Disorder (ADHD) at the … Read the full press release
Posted in Healthcare, Ireland, Pharma & Biotech
Tagged ADHD research, American Psychiatric Association, Norman Atkins, Shire
https://youtu.be/sx11gbYMRFs Spoken word performer communicates plight of adults with ADHD who remain overlooked and unsupported. ZUG, 25-Oct-2016 — /EuropaWire/ — To mark ADHD Awareness Month, Shire plc (LSE: SHP, NASDAQ: SHPG) has today launched a powerful spoken word video to communicate … Read the full press release
Posted in Healthcare, Non Profit, Society, Switzerland
Tagged ADHD, adults ADHD, powerful spoken word video, raise awareness, Shire
Approval follows positive data from clinical studies on efficacy and tolerability, as well as infusion time and number of injection sites Lexington, Mass., 14-Sep-2016 — /EuropaWire/ — Shire plc (LSE: SHP, NASDAQ: SHPG) announced that the United States Food and Drug … Read the full press release
Integration on track; operating cost synergy expectations increased Pipeline progression continues with FDA approval of XIIDRA for dry eye disease DUBLIN, 04-Aug-2016 — /EuropaWire/ — Shire plc (“Shire”) (LSE: SHP, NASDAQ: SHPG) announces unaudited results for the three months ended June … Read the full press release
Posted in Healthcare, Ireland, Management, Pharma & Biotech, Switzerland
Tagged Baxalta, biotechnology company, Shire
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?